The "Understanding Active Pharmaceutical Ingredients (APIs) Training Course (Apr 29th - Apr 30th, 2026)" training has been added to ResearchAndMarkets.com's offering. An active pharmaceutical ...

AUSTIN, Texas and TOKYO, Oct. 3, 2025 /PRNewswire/ -- According to DataM Intelligence, the Active Pharmaceutical Ingredients Market Size reached US$ 238.7 Billion in 2024, up from US$ 224.7 Billion in ...

DUBLIN--(BUSINESS WIRE)--The "Active Pharmaceutical Ingredients (APIs) Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global active ...

ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market. To ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Specialty Active Pharmaceutical Ingredients (API) Market: Global Industry Analysis and Opportunity Assessment, ...

The traditional APIs segment accounted for the largest share in 2024, whereas the HPAPI segment is expected to grow at the fastest CAGR over the forecast period. The HPAPI segment is further segmented ...

The Global Active Pharmaceutical Ingredients (API) Market is valued at USD 209.80 Billion in 2024 and is projected to reach a value of USD 445.7 Billion by 2035 at a CAGR (Compound Annual Growth Rate) ...

The Sterile Dry Powder API Market is witnessing robust growth driven by the increasing adoption of injectable drugs, expansion of biologics manufacturing, and the rising prevalence of chronic diseases ...

Protein aggregation and active principle ingredients (API) stability are factors that ultimately impact both the usability and quality of many biopharmaceutical products, especially injectables. The ...

July 20, 2009, Germantown WI, USA - Cambridge Major Laboratories (CML) announced it will be Dedicating its new large scale Active Pharmaceutical Ingredient (API) manufacturing facility in Germantown, ...

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active ...